Nanobiotix Crecimiento futuro
Future controles de criterios 5/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Nanobiotix de 55.9% y 23% respectivamente, mientras que el BPA crecerá en un 55.7% al año.
Información clave
55.9%
Tasa de crecimiento de los beneficios
55.68%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Biotechs | 59.6% |
| Tasa de crecimiento de los ingresos | 23.0% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Good |
| Última actualización | 21 Jul 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
NANO: CONVERGE Data Will Drive Bullish Repricing Despite Execution Risks
The analyst price target for Nanobiotix has moved from €21.50 to €40.00, with analysts citing updated efficacy data from the Phase 2 CONVERGE study and recent target increases to around €60.00 as key drivers of their revised outlook. Analyst Commentary Recent research updates around Nanobiotix focus heavily on how the Phase 2 CONVERGE efficacy data may affect long term execution, growth prospects and valuation risk.
NANO: CONVERGE Lung Cancer Data Will Drive Repricing Of Future Prospects
Nanobiotix sees its analyst fair value estimate move from €29.24 to €47.80, with analysts pointing to recent upward revisions in price targets following updated CONVERGE study data as key support for the change. Analyst Commentary Recent research updates on Nanobiotix focus on the latest efficacy readouts from the Phase 2 CONVERGE study and how these data points feed into valuation frameworks and execution risk for the company.
NANO: CONVERGE Lung Cancer Data Will Drive Repricing Of Future Prospects
Analysts have raised their fair value estimate for Nanobiotix from €45.00 to €60.00, citing recent price target increases and supportive efficacy data from updated Phase 2 CONVERGE study results. Analyst Commentary Recent Street research on Nanobiotix reflects a cluster of higher price targets following updated efficacy data from the Phase 2 CONVERGE study.Single Asset Reliance And Trial Uncertainty Will Constrain Long Term Earnings Potential
Catalysts About Nanobiotix Nanobiotix develops nanoparticle based drug candidates intended to improve the effectiveness of existing cancer treatments such as radiotherapy and complex systemic therapies. What are the underlying business or industry changes driving this perspective?Radiotherapy Partnership And Curadigm Platform Will Shape A Transformative Future For Cancer Treatment
Catalysts About Nanobiotix Nanobiotix develops nanotechnology based therapies designed to work alongside existing cancer treatments such as radiotherapy. What are the underlying business or industry changes driving this perspective?Radiotherapy Expansion And Nanoprimer Platform Will Shape Long Term Outlook For This Biotech
Catalysts About Nanobiotix Nanobiotix is a biotechnology company focused on nanoscale therapies designed to work with existing treatments such as radiotherapy and complex biologic drugs. What are the underlying business or industry changes driving this perspective?New Forecasts: Here's What Analysts Think The Future Holds For Nanobiotix S.A. (EPA:NANO)
Nanobiotix S.A. ( EPA:NANO ) shareholders will have a reason to smile today, with the analysts making substantial...Risks Still Elevated At These Prices As Nanobiotix S.A. (EPA:NANO) Shares Dive 27%
Nanobiotix S.A. ( EPA:NANO ) shareholders won't be pleased to see that the share price has had a very rough month...Some Confidence Is Lacking In Nanobiotix S.A. (EPA:NANO) As Shares Slide 26%
To the annoyance of some shareholders, Nanobiotix S.A. ( EPA:NANO ) shares are down a considerable 26% in the last...Nanobiotix S.A.'s (EPA:NANO) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
The Nanobiotix S.A. ( EPA:NANO ) share price has fared very poorly over the last month, falling by a substantial 27...Subdued Growth No Barrier To Nanobiotix S.A. (EPA:NANO) With Shares Advancing 26%
Nanobiotix S.A. ( EPA:NANO ) shareholders are no doubt pleased to see that the share price has bounced 26% in the last...We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Is Nanobiotix (EPA:NANO) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 88 | 33 | 86 | 56 | 6 |
| 12/31/2027 | 43 | 0 | 15 | -12 | 6 |
| 12/31/2026 | 38 | -12 | -24 | -23 | 6 |
| 12/31/2025 | 33 | -24 | -34 | -33 | N/A |
| 9/30/2025 | 21 | -38 | -33 | -32 | N/A |
| 6/30/2025 | 10 | -52 | -32 | -31 | N/A |
| 3/31/2025 | 1 | -60 | -26 | -25 | N/A |
| 12/31/2024 | -7 | -68 | -20 | -20 | N/A |
| 9/30/2024 | 18 | -51 | -11 | -10 | N/A |
| 6/30/2024 | 42 | -33 | -2 | -1 | N/A |
| 3/31/2024 | 39 | -37 | -7 | -7 | N/A |
| 12/31/2023 | 36 | -40 | -13 | -12 | N/A |
| 9/30/2023 | 21 | -49 | -25 | -25 | N/A |
| 6/30/2023 | 7 | -59 | -37 | -37 | N/A |
| 3/31/2023 | 6 | -58 | -37 | -37 | N/A |
| 12/31/2022 | 5 | -57 | -37 | -37 | N/A |
| 9/30/2022 | 4 | -50 | -35 | -35 | N/A |
| 6/30/2022 | 3 | -43 | -33 | -32 | N/A |
| 3/31/2022 | 3 | -45 | -31 | -31 | N/A |
| 12/31/2021 | 3 | -47 | -30 | -30 | N/A |
| 9/30/2021 | 2 | -45 | -30 | -30 | N/A |
| 6/30/2021 | 2 | -43 | -30 | -30 | N/A |
| 3/31/2021 | 2 | -39 | -29 | -29 | N/A |
| 12/31/2020 | 2 | -34 | -28 | -28 | N/A |
| 9/30/2020 | 2 | -41 | -31 | -30 | N/A |
| 6/30/2020 | 2 | -48 | -33 | -33 | N/A |
| 3/31/2020 | 2 | -49 | -38 | -37 | N/A |
| 12/31/2019 | 3 | -51 | -43 | -41 | N/A |
| 9/30/2019 | 3 | -46 | N/A | -37 | N/A |
| 6/30/2019 | 3 | -42 | N/A | -33 | N/A |
| 3/31/2019 | 3 | -36 | N/A | -30 | N/A |
| 12/31/2018 | 3 | -30 | N/A | -26 | N/A |
| 9/30/2018 | 4 | -28 | N/A | -24 | N/A |
| 6/30/2018 | 4 | -27 | N/A | -22 | N/A |
| 3/31/2018 | 4 | -26 | N/A | -22 | N/A |
| 12/31/2017 | 4 | -26 | N/A | -21 | N/A |
| 9/30/2017 | 4 | -25 | N/A | -20 | N/A |
| 6/30/2017 | 4 | -24 | N/A | -19 | N/A |
| 3/31/2017 | 5 | -23 | N/A | -19 | N/A |
| 12/31/2016 | 5 | -22 | N/A | -18 | N/A |
| 9/30/2016 | 5 | -21 | N/A | -19 | N/A |
| 6/30/2016 | 5 | -19 | N/A | -20 | N/A |
| 3/31/2016 | 5 | -18 | N/A | -19 | N/A |
| 12/31/2015 | 4 | -17 | N/A | -17 | N/A |
| 9/30/2015 | 4 | -15 | N/A | -15 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que NANO sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.5%).
Beneficios vs. Mercado: Se prevé que NANO sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.
Beneficios de alto crecimiento: Se espera que NANO sea rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (23% al año) de NANO crezcan más rápidamente que los del mercado French (5.8% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (23% al año) de NANO crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de NANO se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/29 18:18 |
| Precio de las acciones al final del día | 2026/07/29 00:00 |
| Beneficios | 2025/12/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Nanobiotix S.A. está cubierta por 18 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Philippa Gardner | Edison Investment Research |
| Jonathan Miller | Evercore ISI |
| Emmanuel Parot | Gilbert Dupont |